Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACULAR vs BEPADIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion.
Treatment of postoperative inflammation in patients who have undergone cataract extraction,Relief of ocular itching due to seasonal allergic conjunctivitis
Hypertension,Diabetic nephropathy in patients with type 2 diabetes and hypertension,Heart failure (NYHA class II-IV) as adjunctive therapy,Stroke prevention in hypertensive patients with left ventricular hypertrophy
One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.
5 mg orally once daily, increased at 2-week intervals to a maximum of 10 mg once daily if needed.
Terminal half-life: 1.8 hours (ketorolac tromethamine); clinical context: short half-life supports dosing every 6 hours for acute pain, but prolonged in elderly or renal impairment (↑ to 5-6 hours, thus dose reduction required).
12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment
Hepatic metabolism primarily via cytochrome P450 2C9 (CYP2C9).
Primarily metabolized by CYP2C9 to inactive metabolites; also undergoes glucuronidation.
Renal: ~80% as unchanged drug and glucuronide conjugates; biliary/fecal: ~20%
Primarily renal excretion (70-80% unchanged) with minor biliary/fecal elimination (10-15%)
99% bound; primary binding protein: albumin.
95-98% bound primarily to albumin
0.11-0.25 L/kg; clinical meaning: low Vd indicates primarily confined to extracellular compartment (plasma and interstitial fluid), minimal tissue penetration.
0.2-0.4 L/kg indicating moderate tissue distribution
Ophthalmic: ~2% systemic absorption after topical instillation (due to corneal permeability and nasolacrimal drainage); oral formulation not used for Acular (ophthalmic only).
Oral: 60-75%; complete with IV administration
No dosage adjustment required for renal impairment.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, reduce dose by 50% or increase dosing interval to every other day.
No dosage adjustment required for hepatic impairment.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Use not recommended.
Safety and efficacy in pediatric patients have not been established; use not recommended.
Not approved for pediatric use.
No specific dosage adjustment required; use same dosing as for younger adults.
Initiate at 2.5 mg once daily; titrate slowly due to increased sensitivity and risk of falls.
No FDA boxed warning.
None
May increase bleeding time due to inhibition of platelet aggregation; use with caution in patients with known bleeding tendencies or those receiving other medications that may prolong bleeding time.,May cause corneal effects including keratitis and corneal thinning; discontinue if corneal epithelial breakdown occurs.,Use with caution in patients with prior sensitivity to aspirin, phenylacetic acid derivatives, or other NSAIDs.,May delay wound healing or exacerbate infections; avoid use in patients with active epithelial herpes simplex keratitis.
Fetal toxicity: Use in pregnancy can cause fetal harm; discontinue as soon as possible when pregnancy is detected,Hypotension in volume-depleted patients,Renal function deterioration in patients with bilateral renal artery stenosis or single kidney,Hyperkalemia, especially in renal impairment or concomitant use of potassium-sparing diuretics,Avoid use with aliskiren in patients with diabetes
Hypersensitivity to ketorolac tromethamine or any component of the formulation,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Active epithelial herpes simplex keratitis,Late pregnancy (third trimester) due to risk of premature closure of ductus arteriosus
Pregnancy (second and third trimesters),Hypersensitivity to bepadin or any component,Concomitant use with aliskiren in patients with diabetes or renal impairment (GFR <60 m L/min)
No known food interactions. Avoid alcohol if concomitant oral NSAIDs are used due to increased risk of gastrointestinal bleeding, but this is not specific to ophthalmic use.
No significant food interactions reported. Grapefruit juice does not affect bepotastine metabolism. Avoid excessive alcohol intake due to potential for increased sedation.
Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairment in the third trimester. First and second trimester use should be avoided unless clearly needed. The potential benefits should be weighed against the risks.
Limited data in humans. In animal studies, no teratogenic effects at therapeutic doses. Increased risk of fetal loss and reduced fetal weight at toxic doses. First trimester: avoid unless benefit outweighs risk. Second/third trimester: use with caution; may cause fetal bradycardia and hypotension.
Ketorolac is excreted in human milk at low levels. The M/P ratio is not well defined. Due to potential adverse effects in nursing infants, caution is advised. Use only if clearly indicated and consider alternative agents.
Not known if excreted in human milk. M/P ratio not established. Caution advised; consider risk-benefit. Monitor infant for excessive sedation and feeding difficulties.
No specific dose adjustments are recommended for pregnancy; however, use the lowest effective dose for the shortest duration due to potential fetal risks. Physiological changes in pregnancy (increased volume of distribution, renal clearance) may alter pharmacokinetics, but no formal studies justify dose modification.
No standard dose adjustment recommended; however, increased renal clearance and volume of distribution may require dose increase or more frequent administration. Monitor clinical response and adjust based on therapeutic drug monitoring if available.
ACULAR (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Avoid concomitant use with other NSAIDs or corticosteroids due to increased risk of corneal adverse events. Use with caution in patients with bleeding disorders or those on anticoagulants, as it may increase bleeding tendency. Monitor for corneal toxicity, especially in patients with compromised corneal integrity. Ensure proper storage at room temperature and discard if solution changes color or becomes cloudy.
BEPADIN (bepotastine besilate), a second-generation antihistamine, is indicated for allergic rhinitis and urticaria. It does not require hepatic metabolism, making it suitable for patients with liver impairment. Onset of action is within 1 hour. Avoid concurrent use with CNS depressants due to additive sedative effects.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not use while wearing soft contact lenses, as the preservative may be absorbed.,Report any signs of corneal problems such as pain, redness, or vision changes immediately.,Use exactly as prescribed and do not share the medication with others.
Take once daily in the morning or as directed by your physician.,Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause drowsiness.,Avoid alcohol consumption as it can intensify drowsiness.,Report any severe allergic reactions, such as difficulty breathing or swelling, to your healthcare provider immediately.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACULAR vs BEPADIN, answered by our medical review team.
ACULAR is a NSAID Ophthalmic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. BEPADIN is a Ophthalmic Antihistamine that works by Angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACULAR and BEPADIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACULAR is: One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.. The standard adult dose of BEPADIN is: 5 mg orally once daily, increased at 2-week intervals to a maximum of 10 mg once daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACULAR and BEPADIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACULAR is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairm. BEPADIN is classified as Category C. Limited data in humans. In animal studies, no teratogenic effects at therapeutic doses. Increased risk of fetal loss and reduced fetal weight at toxic doses. First trimester: avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.